phylogica patents at the uspto, page-8

I've seen Steward speak at a Genesis AGM. He seems to be a very capable biotech director/manager.

It should be noted that he is part of a biotech venture capital team. The thing with teams is that there is room for specialisation in role. In Stewart's case - it was indicated that he was interested in early phase biotech. I presume his reasons for leaving were that Phylogica is no longer early phase - they are about to transact their first major deal.

If you consider the leadership resources at Phylogica - I don't think they are lacking, in this capacity.

The most important dimension is the science: if you have read Paul Watt's Nature review on Phylomers - this tends to remove all doubt over effective scientific leadership. If you read Paul's bio - this removes doubt about clinical leadership.

Harry Karelis has the mantle of Managing Director, in terms of external relationships. I have only hear him speak to the recent company slide presentation - via video download. He seems to be focused on the right things. He has at least one major pharma deal in his sights. This deal will be company making ...

I, for one, remain confident that the board has the experience to manage and the scientific and business development leaders have the brains and creativity to close the big deal. Hopefully a really big deal ...